News Page

Xinnate Appoints Erik Kinnman as Chairman of the Board

12 June, 2026

Xinnate utser Erik Kinnman till styrelseordförande

12 June, 2026

Xinnate får FDAs Fast Track-status för TCP-25 vid behandling av epidermolysis bullosa

10 June, 2026

Xinnate receives FDA Fast Track Designation for TCP-25 for the Treatment of Epidermolysis Bullosa

10 June, 2026

Xinnate granted patent in Japan for TCP-25 formulation. The patent further strengthens the global intellectual property protection of the TCP-25 gel.

18 February, 2026

Xinnate AB har fått patent godkänt i Japan avseende formulering av TCP-25. Patentet är innebär ett ytterligare stärkt globalt immateriellt skydd för TCP-25 gelen.

18 February, 2026

Xinnate announces that recruitment has started and the first patient has been included in the STEP study with TCP-25

30 January, 2026

Xinnate meddelar att rekryteringen har startat och första patienten har blivit inkluderad i STEP-studien med TCP-25

30 January, 2026

First Scientific Publication Reporting Clinical Trial Results for Xinnate’s Proprietary Drug Candidate TCP-25

22 December, 2025

Xinnate Completes Oversubscribed Share Issue of SEK 38,5m

18 December, 2025

debra Care Conference: 26-29 July 2026

The 3rd World Congress on Rare Skin Diseases: 01-03 July 2026

BIO International Convention: 22-25 June 2026

EADV Symposium 2026: 07-09 May 2026

EB 2026: 20-22 Jan 2026

EB Awareness week: 25-31 Oct 2025

NLS Days: 13-14 Oct 2025

ESDR MEETING: 10-13 Sep 2025